INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting
RARITAN, N.J. and NEW ORLEANS, Nov. 3, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen Research & Deve... Biopharmaceuticals, Nephrology Janssen, INVOKANA, canagliflozin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Marketing | Urology & Nephrology